161 related articles for article (PubMed ID: 35182660)
1. Management of portal hypertension in patients treated with atezolizumab and bevacizumab for hepatocellular carcinoma.
Ollivier-Hourmand I; Allaire M; Cervoni JP;
J Hepatol; 2022 Aug; 77(2):566-567. PubMed ID: 35182660
[No Abstract] [Full Text] [Related]
2. Portal hypertension, advanced hepatocellular carcinoma and therapy by atezolizumab-bevacizumab: A "menage à trois" !
Campion B; Larrey E; Wagner M; Rudler M; Thabut D; Allaire M
Clin Res Hepatol Gastroenterol; 2022 Feb; 46(2):101785. PubMed ID: 34384926
[No Abstract] [Full Text] [Related]
3. Reply to: 'Management of portal hypertension in patients treated with atezolizumab and bevacizumab for hepatocellular carcinoma'.
de Franchis R; Bosch J; Garcia-Tsao G; Reiberger T; Ripoll C
J Hepatol; 2022 Aug; 77(2):567-568. PubMed ID: 35526788
[No Abstract] [Full Text] [Related]
4. Reduced-Dose or Discontinuation of Bevacizumab Might Be Considered after Variceal Bleeding in Patients with Hepatocellular Carcinoma Receiving Atezolizumab/Bevacizumab: Case Reports.
Yeom KM; Song YG; Yoo JJ; Kim SG; Kim YS
Medicina (Kaunas); 2024 Jan; 60(1):. PubMed ID: 38256417
[No Abstract] [Full Text] [Related]
5. Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study.
Lee MS; Ryoo BY; Hsu CH; Numata K; Stein S; Verret W; Hack SP; Spahn J; Liu B; Abdullah H; Wang Y; He AR; Lee KH;
Lancet Oncol; 2020 Jun; 21(6):808-820. PubMed ID: 32502443
[TBL] [Abstract][Full Text] [Related]
6. Two cases of rapid progression of esophageal varices after atezolizumab-bevacizumab treatment for hepatocellular carcinoma.
Furusawa A; Naganuma A; Suzuki Y; Hoshino T; Yasuoka H; Tamura Y; Naruse H; Hatanaka T; Kakizaki S
Clin J Gastroenterol; 2022 Apr; 15(2):451-459. PubMed ID: 35179703
[TBL] [Abstract][Full Text] [Related]
7. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.
Finn RS; Qin S; Ikeda M; Galle PR; Ducreux M; Kim TY; Kudo M; Breder V; Merle P; Kaseb AO; Li D; Verret W; Xu DZ; Hernandez S; Liu J; Huang C; Mulla S; Wang Y; Lim HY; Zhu AX; Cheng AL;
N Engl J Med; 2020 May; 382(20):1894-1905. PubMed ID: 32402160
[TBL] [Abstract][Full Text] [Related]
8. Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial.
Galle PR; Finn RS; Qin S; Ikeda M; Zhu AX; Kim TY; Kudo M; Breder V; Merle P; Kaseb A; Li D; Mulla S; Verret W; Xu DZ; Hernandez S; Ding B; Liu J; Huang C; Lim HY; Cheng AL; Ducreux M
Lancet Oncol; 2021 Jul; 22(7):991-1001. PubMed ID: 34051880
[TBL] [Abstract][Full Text] [Related]
9. FDA Approval Summary: Atezolizumab Plus Bevacizumab for the Treatment of Patients with Advanced Unresectable or Metastatic Hepatocellular Carcinoma.
Casak SJ; Donoghue M; Fashoyin-Aje L; Jiang X; Rodriguez L; Shen YL; Xu Y; Jiang X; Liu J; Zhao H; Pierce WF; Mehta S; Goldberg KB; Theoret MR; Kluetz PG; Pazdur R; Lemery SJ
Clin Cancer Res; 2021 Apr; 27(7):1836-1841. PubMed ID: 33139264
[TBL] [Abstract][Full Text] [Related]
10. Current Role of Atezolizumab Plus Bevacizumab Therapy in the Sequential Treatment of Unresectable Hepatocellular Carcinoma.
Komatsu S; Yano Y; Fujishima Y; Ishida J; Kido M; Kuramitsu K; Yamamoto A; Goto T; Yanagimoto H; Toyama H; Ueda Y; Kodama Y; Fukumoto T
Anticancer Res; 2022 Mar; 42(3):1403-1412. PubMed ID: 35220233
[TBL] [Abstract][Full Text] [Related]
11. [New approval: Atezolizumab and bevacizumab for first line of unresecable hepatocellular carcinoma].
Minot-This MS; Edeline J
Bull Cancer; 2021 Feb; 108(2):139-140. PubMed ID: 33546873
[No Abstract] [Full Text] [Related]
12. High Levels of Antidrug Antibodies Against Atezolizumab as a Predictive Marker for Clinical Outcomes in Patients With Hepatocellular Carcinoma-Reply.
Kim C; Yang H; Chon HJ
JAMA Oncol; 2023 May; 9(5):725-726. PubMed ID: 36928517
[No Abstract] [Full Text] [Related]
13. Efficacy and safety of atezolizumab plus bevacizumab in patients with portal hypertension for unresectable hepatocellular carcinoma.
Kinami T; Uchikawa S; Kawaoka T; Yamasaki S; Kosaka M; Johira Y; Yano S; Amioka K; Naruto K; Yamaoka K; Fujii Y; Fujino H; Nakahara T; Ono A; Murakami E; Okamoto W; Yamauchi M; Miki D; Tsuge M; Oka S
Cancer Med; 2024 Mar; 13(5):e7025. PubMed ID: 38477514
[TBL] [Abstract][Full Text] [Related]
14. Hyperprogression in a Patient With Hepatocellular Cancer Treated With Atezolizumab and Bevacizumab: A Case Report and Review of Literature.
Singh B; Kaur P; Maroules M
J Investig Med High Impact Case Rep; 2021; 9():2324709621992207. PubMed ID: 33787380
[TBL] [Abstract][Full Text] [Related]
15. Isolated Adrenocorticotropic Hormone Deficiency Associated with Atezolizumab and Bevacizumab Administration for Treating Hepatocellular Carcinoma: A Case Series.
Ikeda Y; Sato S; Omu R; Nishimura A; Arii S; Uchida R; Nomura K; Sato S; Murata A; Shimada Y; Genda T
Intern Med; 2023 Nov; 62(22):3341-3346. PubMed ID: 37032085
[TBL] [Abstract][Full Text] [Related]
16. Fibrolamellar hepatocellular carcinoma treated with atezolizumab and bevacizumab: two case reports.
Al Zahrani A; Alfakeeh A
J Med Case Rep; 2021 Mar; 15(1):132. PubMed ID: 33722275
[TBL] [Abstract][Full Text] [Related]
17. Risk of Variceal Bleeding in Patients With Advanced Hepatocellular Carcinoma Receiving Atezolizumab/Bevacizumab.
Ha Y; Kim JH; Cheon J; Jeon GS; Kim C; Chon HJ
Clin Gastroenterol Hepatol; 2023 Aug; 21(9):2421-2423.e2. PubMed ID: 35944830
[No Abstract] [Full Text] [Related]
18. A Case of Pseudoprogression in Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab.
Watanabe Y; Ogawa M; Tamura Y; Suda S; Kaneko M; Kumagawa M; Hirayama M; Matsumoto N; Yamamoto T; Moriyama M
J Investig Med High Impact Case Rep; 2021; 9():23247096211058489. PubMed ID: 34845921
[TBL] [Abstract][Full Text] [Related]
19. Conversion surgery for hepatocellular carcinoma with portal vein tumor thrombus after successful atezolizumab plus bevacizumab therapy: a case report.
Hidaka Y; Tomita M; Desaki R; Hamanoue M; Takao S; Kirishima M; Ohtsuka T
World J Surg Oncol; 2022 Jul; 20(1):228. PubMed ID: 35831894
[TBL] [Abstract][Full Text] [Related]
20. Significant response to atezolizumab plus bevacizumab treatment in unresectable hepatocellular carcinoma with major portal vein tumor thrombus: a case report.
Komatsu S; Fujishima Y; Kido M; Kuramitsu K; Goto T; Yanagimoto H; Toyama H; Fukumoto T
BMC Gastroenterol; 2021 Dec; 21(1):470. PubMed ID: 34911458
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]